Trial Profile
A Multicenter Phase 4, Open-label, Single-arm, Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Mar 2024
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Gonadotropin releasing hormone
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 22 Mar 2024 Status changed from active, no longer recruiting to completed.
- 03 Nov 2023 Planned End Date changed from 30 Nov 2023 to 30 Nov 2024.
- 03 Nov 2023 Planned primary completion date changed from 30 Nov 2023 to 30 Nov 2024.